Browsing Tag
Oncology
318 posts
Everest Medicines gains FDA approval for EVM14 cancer vaccine, boosting mRNA oncology pipeline
Everest Medicines secures FDA approval for EVM14, its first internally developed mRNA cancer vaccine, paving the way for global clinical trials.
AstraZeneca moves deeper into cell therapy with $1bn EsoBiotec acquisition
AstraZeneca’s $1 billion acquisition of EsoBiotec signals a major shift in cell therapy innovation. Find out how this deal could transform cancer treatment.
Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more.
Elevation Oncology strengthens cancer drug pipeline as cash reserves hit $93m
Elevation Oncology, Inc. has released its financial results for the fourth quarter and full-year 2024, outlining significant progress…
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a…
PAVmed secures $2.4m to advance Veris Health’s implantable cancer monitoring technology
PAVmed Inc., a diversified commercial-stage medical technology company, has completed a $2.37 million private placement financing, reinforcing its…
KKR takes controlling stake in India’s cancer care giant Healthcare Global Enterprises in $400m deal
In a landmark deal set to transform India’s oncology landscape, KKR, a global investment giant, has signed definitive…
Moleculin Biotech moves forward with pivotal Annamycin trial in AML after FDA backing
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing innovative treatments for acute myeloid leukemia,…
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking…
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…